Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359395 | 0.95 | MDK (0.41) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL15369054 | 0.94 | MDK (0.40) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL16018230 | 0.91 | LMNA (0.37) | MDKLMNASMN1; SMN2 | |
| SCHEMBL12673989 | 0.90 | MDK (0.39) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL18333362 | 0.90 | MDK (0.39) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL15369100 | 0.90 | MDK (0.41) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL15369094 | 0.89 | MDK (0.41) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL18333344 | 0.89 | MAPK1 (0.42) | MDKMAPK1B4GALT1LGALS3MEN1 | |
| SCHEMBL18333308 | 0.87 | LMNA (0.45) | MDKMAPK1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL12673872 | 0.86 | MAPK1 (0.45) | MDKMAPK1B4GALT1LGALS3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | MDK 1849/4885MAPK1 4706/4885B4GALT1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.